Is CRISPR Therapeutics AG (CRSP) a Buy, Sell, or Hold?
CRISPR Therapeutics AG
NASDAQ:CRSP
$50.46 USD
-$0.17 (-0.34%)
- Volume
- 1.73M
- Average Volume
- 1.77M
- Market Capitalization
- $4.87B
- P/E Ratio
- -8.11
- Dividend Yield
- 0.00%
- Price Target
- $76.00
- Year High
- $78.48
- Year Low
- $44.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $17.96
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Samarth Kulkarni |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CRSP |
| CUSIP | H17182108 |
| CIK | 0001674416 |
| Web | https://www.crisprtx.com |
| Phone | 41 41 561 32 77 |
| Currency | USD |
| Employees | 393 |
| Country | CH |
Liquidity
| Debt-to-Equity Ratio | 0.43 |
| Payout Ratio | 0.00 |
| Current Ratio | 17.96 |
| Quick Ratio | 17.96 |
| Cash Ratio | 3.11 |
Sales & Book Value
| Annual Sales | $3.51M |
| Price / Sales | 1186.16 |
| Cash Flow | -4.18 |
| Price / Cash Flow | -12.13 |
| Price / Book | 2.67 |
Price Target and Rating
| Average Stock Price Forecast | $76.00 |
| High Stock Price Forecast | $82.00 |
| Low Stock Price Forecast | $56.00 |
| Forecast Upside/Downside | -33.61% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 38 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-6.47 |
| Trailing P/E Ratio | -8.11 |
| PEG Ratio | 0.25 |
| P/E Growth | 0.25 |
| Net Income | $-581.6M |
| Net Margin | -13856.54% |
| Pretax Margin | -13774.56% |
| Return on Equity | -30.88% |
| Return on Assets | -20.86% |
Financials Score
| AltmanZ Score | 2.48 |
| Piotroski Score | 3.00 |
| Working Capital | 2.31B |
| Total Assets | 2.73B |
| Ebit | -565.17M |
| Market Cap | 4.87B |
| Total Liabilities | 911.26M |
Poll Results
About CRISPR Therapeutics AG (NASDAQ:CRSP) Stock
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own ... hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
2026-07-14 10:01:21
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts
2026-07-10 18:51:09
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session.
3 Reasons to Buy CRISPR Therapeutics Stock
2026-07-10 13:00:00
CRISPR Therapeutics is a good pick to ride the gene editing revolution. The company boasts multiple catalysts on the way and an approved product with a large addressable market.
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
2026-07-08 05:45:00
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
2026-07-07 19:01:18
CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now
2026-07-07 13:45:00
CRISPR Therapeutics has developed a cutting-edge gene-editing biotechnology. Unlike many of its peers, CRISPR has plenty of developmental funding for the next few years.
Progress Report: How Our Top Stock Picks of 2026 Are Faring
2026-07-07 13:05:50
Subscribers to our Substack, The Contrarian Edge , received this commentary on Sunday, July 5.
2026-07-07 10:36:52
CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pipeline.
Frequently Asked Questions
-
What is the current CRISPR Therapeutics AG (CRSP) stock price?
-
CRISPR Therapeutics AG(NASDAQ:CRSP) stock price is $50.46 in the last trading session. During the trading session, CRSP stock reached the peak price of $78.48 while $44.12 was the lowest point it dropped to. The percentage change in CRSP stock occurred in the recent session was --0.34% while the dollar amount for the price change in CRSP stock was -$-0.17.
-
CRSP's industry and sector of operation?
-
The NASDAQ listed CRSP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CRSP?
-
Samarth Kulkarni | Chief Executive Officer & Chairman
Naimish Patel | Chief Medical Officer
Raju Yashaswi Prasad | Chief Financial Officer
Shaun Foy | Co-Founder
Chad A. Cowan | Scientific Founder -
How many employees does CRSP have?
-
Number of CRSP employees currently stands at 393. CRSP operates from Baarerstrasse 14, Zug, ZG 6300, CH.
-
Link for CRSP official website?
-
Official Website of CRSP is: https://www.crisprtx.com
-
How do I contact CRSP?
-
CRSP could be contacted at phone #41 41 561 32 77 and can also be accessed through its website. CRSP operates from Baarerstrasse 14, Zug, ZG 6300, CH.
-
How many shares of CRSP are traded daily?
-
The average number of CRSP shares traded daily for last 3 months was 1.77M.
-
What is the market cap of CRSP currently?
-
The market value of CRSP currently stands at $4.87B with its latest stock price at $50.46